RESUMEN
Small bowel adenocarcinoma (SBA) is a rare tumor with an unfavorable prognosis, and due to its rarity, few studies on its treatment are available. Chemotherapy remains the standard of treatment in advanced disease. Recently immunotherapy has demonstrated to be a valid therapeutic option for many solid tumors. We reviewed the data published in literature to understand the impact of immunotherapy in this cancer.
Asunto(s)
Adenocarcinoma , Neoplasias Duodenales , Neoplasias del Íleon , Neoplasias del Yeyuno , Humanos , Intestino Delgado/patología , Neoplasias del Yeyuno/tratamiento farmacológico , Neoplasias del Yeyuno/patología , Neoplasias del Íleon/tratamiento farmacológico , Neoplasias del Íleon/patología , Neoplasias Duodenales/patología , Neoplasias Duodenales/terapia , Adenocarcinoma/tratamiento farmacológico , Adenocarcinoma/patología , InmunoterapiaRESUMEN
RATIONALE: Peptide receptor radionuclide therapy with 177Lu-Dotatate represents a major breakthrough in the treatment of metastatic well differentiated neuroendocrine tumors. This treatment is generally well tolerated. Reported severe long-term hematological side effects are rare and include hematopoietic neoplasms and bone marrow failure. PATIENTS CONCERNS: We describe the case of a patient presenting spontaneous bleeding and bruising occurring 6âweeks after the first administration of 177Lu-Dotatate. Blood tests showed anemia, thrombocytopenia, prolonged clotting times, profound fibrinolysis and low levels of coagulation factors II and V. There were no signs of tumor lysis syndrome. DIAGNOSES: We made the diagnosis of acute disseminated intravascular coagulation. INTERVENTION: Treatment consisted of multiple transfusions of fresh frozen plasma, fibrinogen and platelets, and corticosteroids. Acute disseminated intravascular coagulation (DIC) persisted for 10âdays and then resolved. OUTCOMES: Metabolic imaging 5âmonths after the 177Lu-Dotatate administration showed disease progression. Treatment with 177Lu-Dotatate was not rechallenged due to the occurrence of DIC. LESSONS: Our case suggests that acute hemorrhagic disseminated intravascular coagulation can be a rare and life-threatening subacute side effect of 177Lu-Dotatate peptide receptor radionuclide therapy.
Asunto(s)
Coagulación Intravascular Diseminada/inducido químicamente , Octreótido/análogos & derivados , Compuestos Organometálicos/efectos adversos , Femenino , Hemorragia/inducido químicamente , Humanos , Neoplasias del Íleon/tratamiento farmacológico , Persona de Mediana Edad , Tumores Neuroendocrinos/tratamiento farmacológico , Octreótido/efectos adversos , Octreótido/uso terapéutico , Compuestos Organometálicos/uso terapéuticoRESUMEN
A 77-year-old woman was admitted to our hospital because of right lower abdominal pain. CT revealed tumors in the ileum and uterine cervix. After a gynecological biopsy of the uterine tumor, we diagnosed Stage â £ diffuse large B-cell lymphoma. We treated her with R-THPCOP chemotherapy. On day 8 after the first chemotherapy, she developed perforated peritonitis, and an emergency partial ileum resection was performed. Histopathologically, viable cells were not found in the resected intestine. Chemotherapy was resumed on postoperative day 21, and she achieved a complete response 8 months after the surgery. Gastrointestinal malignant lymphoma is sometimes reported in cases requiring emergency surgery. Therefore, information sharing between hematologist and surgeon is recommended.
Asunto(s)
Neoplasias del Íleon , Linfoma de Células B Grandes Difuso , Peritonitis , Neoplasias del Cuello Uterino , Anciano , Femenino , Humanos , Neoplasias del Íleon/tratamiento farmacológico , Neoplasias del Íleon/cirugía , Íleon , Linfoma de Células B Grandes Difuso/tratamiento farmacológico , Peritonitis/etiología , Neoplasias del Cuello Uterino/cirugíaRESUMEN
PURPOSE: Complete upfront resection of pediatric gastrointestinal lymphomas is recommended over biopsy whenever feasible, but either approach may have adverse sequelae. We sought to compare gastrointestinal and oncological outcomes of pediatric gastrointestinal lymphomas who underwent attempted upfront resection or biopsy of the presenting bowel mass. METHODS: We retrospectively reviewed charts of children with gastrointestinal lymphomas treated on LMB89 and LMB96 protocols from 2000 to 2019 who underwent upfront gastrointestinal surgery, and compared resection and biopsy groups. RESULTS: Of 33 children with abdominal lymphomas, 20 had upfront gastrointestinal surgery-10 each had resection or biopsy. Patients with attempted upfront resections had fewer postoperative gastrointestinal complications compared to biopsies (10% vs. 60%, p = 0.057), but longer time to chemotherapy initiation (median 11.5 vs. 4.5 days, p < 0.001). Three resection patients were surgically down-staged. Second surgeries were required in 30% and 40% of resected and biopsied patients, respectively, at median 4.6 months. Survival was similar in both groups, but better in patients on LMB96 protocol and stage II/III disease. CONCLUSIONS: Children with upfront attempted resection had low rates of surgical down-staging, greater delay in chemotherapy initiation, but fewer gastrointestinal complications and subsequent surgeries than biopsies. Survival was similar regardless of upfront surgery, likely reflecting beneficial effects of newer protocols.
Asunto(s)
Biopsia , Procedimientos Quirúrgicos del Sistema Digestivo/métodos , Neoplasias del Íleon/cirugía , Linfoma/cirugía , Adolescente , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Niño , Preescolar , Ciclofosfamida/uso terapéutico , Citarabina/uso terapéutico , Femenino , Humanos , Neoplasias del Íleon/tratamiento farmacológico , Neoplasias del Íleon/patología , Lactante , Linfoma/tratamiento farmacológico , Linfoma/patología , Masculino , Metotrexato/uso terapéutico , Estudios RetrospectivosRESUMEN
PURPOSE: Small-bowel adenocarcinoma (SBA) is rare, and no standard of care exists for metastatic disease beyond first-line FOLFOX/CAPOX. SBA has higher rates of microsatellite instability (MSI-H) and T-lymphocyte infiltration than other gastrointestinal cancers. We hypothesize that pembrolizumab, a PD-1 inhibitor, will induce antitumor response. PATIENTS AND METHODS: Patients with previously treated advanced SBA received pembrolizumab 200 mg i.v. every 3 weeks until disease progression (PD), toxicity, or 35 doses maximum. Primary endpoint was confirmed overall response rate (ORR) with secondary progression-free survival (PFS), overall survival (OS), and toxicity assessment endpoints. Outcomes were stratified by tumor location, microsatellite stability (MSS) or instability (MSI-H), and PD-L1 level. RESULTS: Forty patients were treated for a median duration of four cycles (range, 1-35). All patients are off study treatment due to PD (75%), death (10%), 35 cycles completed (8%), refusal (3%), and adverse effects (AEs, 5%). Three confirmed partial responses [PRs; 8%; 95% confidence interval (CI), 2-20] did not meet predefined success criteria of ORR 30%. Median OS (7.1 months; 95% CI, 5.1-17.1) and median PFS (2.8 months; 95% CI, 2.7-4.2) were similar across primary tumor sites. One confirmed PR (3%) was seen in patients with low MSS/MSI tumors and correlated with high tumor mutation burden (TMB). Fifty percent of patients with MSI-H tumors achieved PR and remain alive without progression. Twenty-five patients (63%) had grade ≥3 AEs and 11 patients (28%) had grade 4/5 AEs. CONCLUSIONS: In the largest study of SBA to date, pembrolizumab did not induce the hypothesized response rate; however, we did identify responses in key biomarker-selected cohorts.
Asunto(s)
Adenocarcinoma/tratamiento farmacológico , Anticuerpos Monoclonales Humanizados/uso terapéutico , Neoplasias Duodenales/tratamiento farmacológico , Neoplasias del Íleon/tratamiento farmacológico , Inhibidores de Puntos de Control Inmunológico/uso terapéutico , Neoplasias del Yeyuno/tratamiento farmacológico , Adenocarcinoma/genética , Adenocarcinoma/patología , Adulto , Anciano , Anciano de 80 o más Años , Neoplasias Duodenales/genética , Neoplasias Duodenales/patología , Femenino , Humanos , Neoplasias del Íleon/genética , Neoplasias del Íleon/patología , Neoplasias del Yeyuno/genética , Neoplasias del Yeyuno/patología , Masculino , Inestabilidad de Microsatélites , Persona de Mediana Edad , Estadificación de Neoplasias , Estudios Prospectivos , Resultado del TratamientoRESUMEN
BACKGROUND: Gastrointestinal stromal tumours (GISTs) located in the jejunum or ileum (JI-GIST) are considered worse prognosis compared to those of gastric (G-GIST) location. It has been suggested that this dogma should be revised. The aim of this study was to describe the characteristics of jejunoileal GISTs and its prognosis and to compare them with G-GISTs in the era of imatinib. METHODS: We retrospectively reviewed the clinical histories of all the patients diagnosed with GISTs between January 2000 and November 2016: Clinical and pathological data, as recurrence, metastatic state, disease-free survival (DFS) as well as overall survival (OS) rates of patients were reviewed. RESULTS: JI-GIST patients comprise 29 cases (37.7%). Compared to G-GIST, JI-GIST patients had undergone emergency surgery more frequently (37.9% vs. 10.4%, p = 0.007). According to the NIH-Fletcher classification, the low or very-low risk group represents 17.2% of JI-GISTs as opposed to 37.6% of G-GISTs (p < 0.005). When the AFIP-Miettinen system was used the low or very-low group represented 17.2% of JI-GISTs vs. 58.4% in the G-GISTs group (p < 0.001). Both local recurrence (24.1% vs. 12.5%, p < 0.05) and metastatic rate (34.5% vs. 22.9%, p < 0.05) were higher in the JI-GIST group than in G-GIST. 5- and 10-year DFS and 10-year OS rate were lower for JI-GIST (54.5% and 39.6% vs. 77.2% and 60.8%, and 57.9% vs. 65%, respectively, p < 0.05). CONCLUSIONS: The observed differences between both groups in DFS and OS rates at long term could be attributed to the effect of imatinib.
Asunto(s)
Antineoplásicos/uso terapéutico , Tumores del Estroma Gastrointestinal/tratamiento farmacológico , Tumores del Estroma Gastrointestinal/mortalidad , Neoplasias del Íleon/tratamiento farmacológico , Neoplasias del Íleon/mortalidad , Mesilato de Imatinib/uso terapéutico , Neoplasias del Yeyuno/tratamiento farmacológico , Neoplasias del Yeyuno/mortalidad , Neoplasias Gástricas/tratamiento farmacológico , Neoplasias Gástricas/mortalidad , Anciano , Supervivencia sin Enfermedad , Femenino , Humanos , Masculino , Persona de Mediana Edad , Pronóstico , Estudios Retrospectivos , Tasa de SupervivenciaRESUMEN
INTRODUCTION: Interferon alpha (IFNα) has been used for a long time in patients with functionally active neuroendocrine tumors (NET). However, due to the unfavorable toxicity profile of interferon, the perceived limited efficacy as well as the development of novel substances, IFNα is only used sparingly in the treatment of NET to date. PATIENTS CONCERNS AND DIAGNOSIS: We describe the case of a 63-year-old male patient with highly differentiated, functional NET of the ileum and synchronous liver metastasis. INTERVENTIONS: After failure of classical therapies including dose-intensified somatostatin analog treatment and palliative primary tumor resection, a therapy with pegylated IFNα2a (135âµg/wk) was initiated. Following this treatment, the patient fully recovered from signs of hypersecretion and demonstrated an impressive tumor response. OUTCOMES: Thirty months after initiating IFNα, the patient is still free of clinical symptoms and shows a sustained tumor response. Notably, no relevant side effects were observed. CONCLUSION: Our case report supports the use of IFNα in patients with functional NET refractory to classical treatments.
Asunto(s)
Neoplasias del Íleon/tratamiento farmacológico , Interferón alfa-2/uso terapéutico , Interferón-alfa/uso terapéutico , Tumores Neuroendocrinos/tratamiento farmacológico , Polietilenglicoles/uso terapéutico , Humanos , Neoplasias del Íleon/patología , Masculino , Persona de Mediana Edad , Tumores Neuroendocrinos/patología , Proteínas Recombinantes/uso terapéutico , Insuficiencia del Tratamiento , Resultado del TratamientoRESUMEN
BACKGROUND: Despite recent findings that epithelial cell adhesion molecule (EPCAM) deletions can cause Lynch syndrome (LS), its clinical characteristics are still unknown. We present the first case of ileum cancer in a patient with germline EPCAM gene deletion, which was discovered during ovarian tumor surgery. CASE PRESENTATION: A 59-year-old woman presented with a history of colon cancer occurring at 38 and 55 years old. Five of her siblings had a history of colon cancer, and an elder sister had confirmed LS. As imaging examination revealed an ovarian tumor, and we performed hysterectomy and bilateral salpingo-oophorectomy. Careful observation during surgery revealed a cherry-sized tumor in the ileum, prompting partial ileal resection. Pathological examination showed the ovarian tumor to be a metastasis of ileum cancer. Genetic testing with blood-relative information using multiplex ligation-dependent probe amplification showed EPCAM exons 8 and 9 deletions, confirming LS. The patient received adjuvant chemotherapy with CAPOX (capecitabine and oxaliplatin) and has remained disease-free for 24 months. CONCLUSIONS: We were fortunate to identify ileum cancer that would have been difficult to find preoperatively through careful observation during ovarian tumor surgery and successfully treated the patient by using surgical resection and CAPOX chemotherapy. When treating patients with hereditary cancer syndromes including LS, we should keep all associated cancers in mind.
Asunto(s)
Adenocarcinoma , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Molécula de Adhesión Celular Epitelial/genética , Neoplasias del Íleon , Neoplasias Ováricas , Ovariectomía , Adenocarcinoma/tratamiento farmacológico , Adenocarcinoma/genética , Adenocarcinoma/patología , Adenocarcinoma/cirugía , Capecitabina/administración & dosificación , Neoplasias Colorrectales Hereditarias sin Poliposis/tratamiento farmacológico , Neoplasias Colorrectales Hereditarias sin Poliposis/genética , Neoplasias Colorrectales Hereditarias sin Poliposis/cirugía , Terapia Combinada , Femenino , Mutación de Línea Germinal , Humanos , Neoplasias del Íleon/tratamiento farmacológico , Neoplasias del Íleon/genética , Neoplasias del Íleon/patología , Neoplasias del Íleon/cirugía , Persona de Mediana Edad , Neoplasias Ováricas/tratamiento farmacológico , Neoplasias Ováricas/genética , Neoplasias Ováricas/secundario , Neoplasias Ováricas/cirugía , Oxaliplatino/administración & dosificación , Linaje , Eliminación de Secuencia , Resultado del TratamientoRESUMEN
Small-bowel hemangiomas are a possible source of gastrointestinal bleeding for which there is no established treatment approach. In this report, we describe the case of a 58-year-old woman who presented with hematochezia and who was diagnosed with small bowel hemangioma. She was successfully treated using endoscopic sclerotherapy. Initial capsule endoscopy revealed bleeding in the ileum. Subsequent double-balloon enteroscopy showed a 2-cm, bluish-purple, ileal submucosal tumor with an overlying protrusion. The lesion was responsible for the hematochezia and was treated with intralesional injection of polidocanol. The hematochezia completely resolved and at 4 months after sclerotherapy, the size of the lesion was significantly reduced.
Asunto(s)
Enteroscopía de Doble Balón/métodos , Hemangioma/tratamiento farmacológico , Hemangioma/cirugía , Neoplasias del Íleon/tratamiento farmacológico , Neoplasias del Íleon/cirugía , Polidocanol/uso terapéutico , Soluciones Esclerosantes/uso terapéutico , Escleroterapia/métodos , Femenino , Humanos , Persona de Mediana Edad , Resultado del TratamientoRESUMEN
Everolimus is an mTOR inhibitor, approved as a treatment for cancer and as an immunosuppressant agent in solid organ transplantation; it frequently produces toxic metabolic effects, particularly of the most severe kind. Its use can cause hyperglycemia, hypercholesterolemia and hypertriglyceridemia; thus, metabolic values should be monitored regularly to prevent these adverse events. We present the case of a woman with an intestinal neuroendocrine tumor who developed two episodes of acute pancreatitis, secondary to severe hypertriglyceridemia caused by everolimus. After treatment with fibrates and omega-3, triglyceride levels returned to baseline, without developing new metabolic or digestive complications. Targeted levels of triglyceride for cancer patients treated with everolimus, should be below 500 or 300 mg/dL, depending on whether life expectancy is less or longer than one year, respectively.
Asunto(s)
Antineoplásicos/efectos adversos , Everolimus/efectos adversos , Hipertrigliceridemia/inducido químicamente , Hipolipemiantes/uso terapéutico , Neoplasias del Íleon/tratamiento farmacológico , Tumores Neuroendocrinos/tratamiento farmacológico , Pancreatitis/etiología , Femenino , Humanos , Hipertrigliceridemia/complicaciones , Hipertrigliceridemia/tratamiento farmacológico , Persona de Mediana EdadRESUMEN
BACKGROUND: Malignant melanoma frequently spreads to the gastrointestinal tract, with 60% of patients with advanced metastatic disease showing digestive involvement; however, primary MM of the small intestine is a controversial diagnosis. In fact, whether these lesions arise as true small bowel primary neoplasms or represent metastases from unidentified cutaneous melanomas remains debatable. The most common complications are intestinal obstruction, massive gastrointestinal bleeding, and perforation. OBJECTIVE & METHODS: We report a case of a 64-year-old patient, with an unremarkable medical history, in which a late diagnosis of primary ileal malignant melanoma in the setting of an emergency laparotomy due to small bowel obstruction, and where PET-scan showed costal metastasis. Therefore, we provide a narrative review of the scientific literature about this topic. RESULTS: 36 cases of primary small bowel melanoma, included that in the present study, were found through our search in the scientific literature. CONCLUSION: Primary small bowel MM appears to be an extremely rare entity which clinicians should be more aware of, in order to plan better a correct strategy of early diagnosis and appropriate treatment.
Asunto(s)
Neoplasias del Íleon , Obstrucción Intestinal , Melanoma , Antineoplásicos Alquilantes/uso terapéutico , Dacarbazina/uso terapéutico , Humanos , Neoplasias del Íleon/diagnóstico por imagen , Neoplasias del Íleon/tratamiento farmacológico , Neoplasias del Íleon/patología , Íleon/patología , Obstrucción Intestinal/diagnóstico por imagen , Obstrucción Intestinal/tratamiento farmacológico , Obstrucción Intestinal/patología , Masculino , Melanoma/diagnóstico por imagen , Melanoma/tratamiento farmacológico , Melanoma/patología , Persona de Mediana Edad , Tomografía de Emisión de PositronesAsunto(s)
Antineoplásicos/uso terapéutico , Endometriosis/patología , Tumores del Estroma Gastrointestinal/tratamiento farmacológico , Neoplasias del Íleon/tratamiento farmacológico , Compuestos de Fenilurea/uso terapéutico , Piridinas/uso terapéutico , Sunitinib/uso terapéutico , Adulto , Endometriosis/tratamiento farmacológico , Endometriosis/etiología , Femenino , Tumores del Estroma Gastrointestinal/secundario , Humanos , Neoplasias del Íleon/patología , Neoplasias Hepáticas/secundarioRESUMEN
Primary small bowel cancer is a rare entity; thus, it is often found in progress. Therefore, the prognosis is often poor. Because of its low frequency, there are few reports concerning the treatment for small bowel cancer; hence, it is important to examine individual cases in detail. In this study, we present a case of recurrent small bowel cancer that successfully responded to chemoradiation therapy. Case: A 48-year-old woman had anemia. Colonoscopy showed a tumor in the terminal ileum. Because of invasion in the ovaries and uterus, ileocecal resection, hysterectomy, and bilateral adnexectomy were performed. The pathological diagnosis was small bowel cancer with lymph node metastasis, and CapeOX therapy was administered as postoperative adjuvant chemotherapy. Since local recurrence was detected in the right lower quadrant 6 months after the surgery, IRIS plus BV was initiated. Radiation therapy(2Gy×25 times, total 50 Gy)was also administered within the same period(only S-1 administration during radiation). After radiation therapy, the tumor decreased significantly in size and showed CR. Currently, the patient is under observation without treatment, but she has had no recurrence for 6 years after the confirmation of recurrence(6 years and 6 months after surgery). It is extremely rare for chemoradiation therapy to be effective for recurrent small bowel cancer; we report such a case with literatures.
Asunto(s)
Neoplasias Colorrectales , Neoplasias del Íleon , Quimioradioterapia , Neoplasias Colorrectales/tratamiento farmacológico , Neoplasias Colorrectales/radioterapia , Femenino , Humanos , Neoplasias del Íleon/tratamiento farmacológico , Neoplasias del Íleon/radioterapia , Metástasis Linfática , Persona de Mediana Edad , Recurrencia Local de NeoplasiaRESUMEN
Mastocytosis is a rare and heterogeneous group of disorders that may be limited to the skin and even spontaneously regress or may have a systemic presentation with multi-organ involvement and poor outcome. Among the extracutaneous sites, gastrointestinal tract is often affected, but nonspecific clinical manifestations combined with subtle histological findings of the disease makes the diagnosis of gastrointestinal mastocytosis rather hard. In absence of a high index of suspicion, gastrointestinal involvement is easily overlooked. We report a challenging case of systemic mastocytosis presenting with isolated gastrointestinal manifestations without skin involvement, in which the diagnosis was missed at first evaluation of intestinal biopsies.
Asunto(s)
Médula Ósea/patología , Neoplasias del Íleon/diagnóstico , Íleon/patología , Mucosa Intestinal/patología , Mastocitosis Sistémica/diagnóstico , Anciano , Antineoplásicos/uso terapéutico , Biopsia , Endoscopía Gastrointestinal , Humanos , Neoplasias del Íleon/tratamiento farmacológico , Neoplasias del Íleon/patología , Íleon/diagnóstico por imagen , Mucosa Intestinal/citología , Mucosa Intestinal/diagnóstico por imagen , Masculino , Mastocitos/patología , Mastocitosis Sistémica/tratamiento farmacológico , Mastocitosis Sistémica/patología , Resultado del TratamientoRESUMEN
Objective: To investigate the clinicopathological features, treatment and prognosis of duodenal-type follicular lymphoma. Methods: Four cases of duodenal-type follicular lymphoma diagnosed at Guangdong General Hospital from 2014 to 2015 with detailed clinical data were included. The histomorphology, immunophenotype, treatment and prognoses were analyzed. Results: The patients' age ranged from 51 to 57 years (mean 54 years), and there were 2 males and 2 females. The involved sites were gastric fundus in one case, second portion of the duodenum in two cases and terminal ileum in one case. All patients presented with multiple mucosal granules or nodules at endoscopy. Microscopically, there were multiple mucosal neoplastic follicles, constituting grade 1-2 disease based on nodal follicular lymphoma grading system. The tumor cells were positive for CD20, CD10, bcl-6 and bcl-2. CD21 highlighted the follicular dendritic meshwork mainly at the periphery of the follicles. Proliferation index was low. Three patients received rituximab monotherapy for 4 cycles, leading to complete remission. One patient refused therapy and the disease progressed to systemic lymphoma 15 months after the initial diagnosis. Conclusions: Duodenal-type follicular lymphoma is a special variant of follicular lymphoma with indolent clinical course. The tumor exhibits morphology of low grade follicular lymphoma with characteristic dendritic meshwork at the periphery of the follicles and a low proliferation index. Prognosis is excellent. Rituximab monotherapy is treatment of choice, but a small minority of patients may progress to systemic disease.
Asunto(s)
Neoplasias Duodenales/patología , Neoplasias del Íleon/patología , Linfoma Folicular/patología , Neoplasias Gástricas/patología , Antígenos CD20/análisis , Antineoplásicos Inmunológicos/uso terapéutico , Neoplasias Duodenales/tratamiento farmacológico , Femenino , Fundus Gástrico/patología , Humanos , Neoplasias del Íleon/tratamiento farmacológico , Inmunofenotipificación , Linfoma Folicular/tratamiento farmacológico , Masculino , Persona de Mediana Edad , Pronóstico , Rituximab/uso terapéutico , Neoplasias Gástricas/tratamiento farmacológicoRESUMEN
A randomized phase III trial was initiated in May 2017 to confirm the superiority of post-operative therapy with capecitabine and oxaliplatin over observation in terms of relapse-free survival in patients with curatively resected small bowel adenocarcinoma. Total 150 patients will be enrolled from 20 Japanese institutions over a period of 6.5 years. Relapse-free survival is the primary endpoint, while the secondary endpoints are overall survival, disease-free survival as defined by the Japan Clinical Oncology Group (JCOG), disease-free survival as defined by the International Rare Cancer Initiative (IRCI), and adverse events. Global phase III trial of IRCI to confirm the superiority of post-operative chemotherapy for small bowel adenocarcinoma was started in the UK in August 2015 (ClinicalTrials.gov Identifier: NCT02502370). An integrated analysis of the IRCI trial and our study are planned. Our trial has been registered in the UMIN Clinical Trials Registry as UMIN000027280 (http://www.umin.ac.jp/ctr/index.htm).
Asunto(s)
Adenocarcinoma/tratamiento farmacológico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Capecitabina/uso terapéutico , Neoplasias del Íleon/tratamiento farmacológico , Neoplasias del Yeyuno/tratamiento farmacológico , Oxaliplatino/uso terapéutico , Adolescente , Adulto , Anciano , Supervivencia sin Enfermedad , Femenino , Humanos , Japón , Masculino , Persona de Mediana Edad , Periodo Posoperatorio , Adulto JovenRESUMEN
Primary classic Hodgkin lymphoma of the gastrointestinal tract represents a rare occurrence. A full patient's work-up is essential in order to exclude a secondary intestinal involvement. Histologically Epstein-Barr virus mucocutaneous ulcer closely resembles Hodgkin lymphoma. The differential diagnosis between these two entities is relevant, since both the therapeutic approach and the clinical behavior are different. Herein, we describe a case of primary classic Hodgkin lymphoma arising in the ileum and a case of Epstein-Barr virus mucocutaneous ulcer of the colon, focusing on the main clinicopathological differences.
Asunto(s)
Enfermedades del Colon/patología , Infecciones por Virus de Epstein-Barr/patología , Enfermedad de Hodgkin/patología , Neoplasias del Íleon/patología , Infecciones Oportunistas/patología , Úlcera/patología , Adulto , Anciano de 80 o más Años , Biomarcadores de Tumor/análisis , Biopsia , Enfermedades del Colon/inmunología , Enfermedades del Colon/virología , Diagnóstico Diferencial , Infecciones por Virus de Epstein-Barr/inmunología , Infecciones por Virus de Epstein-Barr/virología , Femenino , Enfermedad de Hodgkin/tratamiento farmacológico , Enfermedad de Hodgkin/metabolismo , Humanos , Neoplasias del Íleon/química , Neoplasias del Íleon/tratamiento farmacológico , Huésped Inmunocomprometido , Inmunohistoquímica , Inmunosupresores/efectos adversos , Masculino , Metotrexato/efectos adversos , Infecciones Oportunistas/inmunología , Infecciones Oportunistas/virología , Valor Predictivo de las Pruebas , Úlcera/inmunología , Úlcera/virologíaRESUMEN
A case of 25- years-old female with NET deriving from Meckel's diverticulum is described. The patient had one year history of dermatological skin problems. Ultrasound examination of abdomen performed because of arterial hypertension, revealed multiple hepatic lesions, which was confirmed in contrast enhanced CT. The typical contrast enhanced metastatic lesions in CT and elevated levels of chromogranin A suggested NET of unknown origin. SRS with 99mTc-HYNICTOC was perform for primary tumor localization, and revealed liver and paraaortic lymph nodes metastases, but no sign of primary tumor location. As a next step for primary tumor localization 68Ga-DOTATATE PET/CT was done, which revealed focus of increased uptake in small intestine considered to be the primary tumor site. The imaging and clinical history of patient was discussed on ENETS Tumor Board. Due to location of primary tumor in the small intestine with no anatomical changes in CT, laparotomy guided with gamma probe after 68Ga-DOTATATE injection was performed. During surgery procedure, the primary tumor was hardly palpable in the tip of Meckel's diverticulum, confirmed by gamma probe. After surgery, tandem peptide receptor radionuclide therapy (PRRT) was started. Patient received 4 doses of 90Y/177Lu-DOTATATE with total activity of 360 mCi (13.32 GBq). The three months follow up 68Ga-DOTATATE PET/CT had shown stable disease of patient. The presented case showed importance role of multidisciplinary team cooperation in patient management. Use of RGS is essential in cases like presented, when the tumor cannot be localized only by surgical palpation.
Asunto(s)
Neoplasias del Íleon/diagnóstico por imagen , Divertículo Ileal/diagnóstico por imagen , Tumores Neuroendocrinos/diagnóstico por imagen , Octreótido/análogos & derivados , Compuestos Organometálicos/uso terapéutico , Adulto , Manejo de la Enfermedad , Femenino , Humanos , Neoplasias del Íleon/diagnóstico , Neoplasias del Íleon/tratamiento farmacológico , Neoplasias del Íleon/cirugía , Tumores Neuroendocrinos/diagnóstico , Tumores Neuroendocrinos/tratamiento farmacológico , Tumores Neuroendocrinos/cirugía , Octreótido/uso terapéutico , Tomografía Computarizada por Tomografía de Emisión de Positrones , Radiofármacos/uso terapéutico , TelemedicinaRESUMEN
BACKGROUND: Adenocarcinomas or combined adeno-neuroendocrine carcinomas (MANEC) of small bowel usually have a dismal prognosis with limited systemic therapy options. This is the first description of a patient showing a germline-related BRCA1 mutated MANEC of his ileum. The tumor presented a susceptibility to a combined chemotherapy and the PARP1-inhibitor olaparib. CASE PRESENTATION: A 74-year old male patient presented with a metastasized MANEC of his ileum. Due to clinical symptoms his ileum-tumor and the single brain metastasis were removed. We verified the same pathogenic (class 5) BRCA1 mutation in different tumor locations. There was no known personal history of a previous malignant tumor. Nevertheless we identified his BRCA1 mutation as germline-related. A systemic treatment was started including Gemcitabine followed by selective internal radiotherapy (SIRT) to treat liver metastases and in the further course Capecitabine but this treatment finally failed after 9 months and all liver metastases showed progression. The treatment failure was the reason to induce an individualized therapeutic approach using combined chemotherapy of carboplatin, paclitaxel and the Poly (ADP-ribose) polymerase- (PARP)-inhibitor olaparib analogous to the treatment protocol of Oza et al. All liver metastases demonstrated with significant tumor regression after 3 months and could be removed. In his most current follow up from December 2017 (25 months after his primary diagnosis) the patient is in a very good general condition without evidence for further metastases. CONCLUSION: We present first evidence of a therapy susceptible germline-related BRCA1 mutation in small bowel adeno-neuroendocrine carcinoma (MANEC). Our findings offer a personalized treatment option. The germline background was unexpected in a 74-year old man with no previously known tumor burden. We should be aware of the familiar background in tumors of older patients as well.
Asunto(s)
Adenocarcinoma/tratamiento farmacológico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Proteína BRCA1/genética , Carcinoma Neuroendocrino/tratamiento farmacológico , Mutación de Línea Germinal , Neoplasias del Íleon/tratamiento farmacológico , Adenocarcinoma/genética , Adenocarcinoma/secundario , Anciano , Neoplasias Encefálicas/secundario , Carboplatino/uso terapéutico , Carcinoma Neuroendocrino/genética , Carcinoma Neuroendocrino/secundario , Humanos , Neoplasias del Íleon/genética , Neoplasias del Íleon/patología , Neoplasias Hepáticas/secundario , Masculino , Paclitaxel/uso terapéutico , Inhibidores de Poli(ADP-Ribosa) Polimerasas/uso terapéuticoRESUMEN
RATIONALE: The small intestine (SI) does not commonly harbor cancer but is occasionally involved by metastatic cancer from other organs. To manage SI cancer appropriately, surveillance for primary origin outside the SI is essential. PATIENT CONCERNS: This study presents a 54-year-old Thai man diagnosed with SI obstruction which required laparoscopy- assisted partial ileal resection. DIAGNOSES: On the basis of the expression pattern of cytokeratins (CKs) and mucins (MUCs) in the resected SI adenocarcinoma, we suspected this was metastasized from the pancreatobiliary tract. Imaging studies revealed a hepatic segmental atrophy with an occlusion of the posterior segmental blanch of the portal vein without any contrast-enhanced lesions in the liver. Pathology of the liver biopsy revealed intrahepatic cholangiocarcinoma (ICC) with the same expression pattern of CKs and MUCs as the SI adenocarcinoma. INTERVENTIONS: Systemic chemotherapy (gemcitabine and cisplatin) was initiated. OUTCOMES: Despite of the chemotherapy for 20 months, he died of ICC. LESSONS: This is the first case of SI obstruction caused by the metastasis of ICC. We demonstrate that immunohistochemical staining of CKs and MUCs discriminate between primary and metastatic SI cancer and predict its primary origin outside the SI. This case also suggests that a hepatic segmental atrophy with portal vein occlusion would be an atypical but important finding to diagnose ICC.